Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 23844222)

1.

Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients.

Pan X, Zhang K, Yang X, Liang J, Sun H, Li X, Zou Y, Xu Q, An G, Li G, Xu Q.

PLoS One. 2013 Jul 3;8(7):e68568. doi: 10.1371/journal.pone.0068568. Print 2013.

2.

Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.

Song MJ, Song do S, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HJ.

World J Gastroenterol. 2012 Nov 21;18(43):6277-83. doi: 10.3748/wjg.v18.i43.6277.

3.

Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.

He D, Guo S, Chen W, Chen X, Yan G, Wang J, Li M, Zhu P, Huang H, Wang Y.

BMC Infect Dis. 2013 Oct 3;13:458. doi: 10.1186/1471-2334-13-458.

4.

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients.

Kim YJ, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, Cho SW.

Clin Mol Hepatol. 2013 Sep;19(3):300-4. doi: 10.3350/cmh.2013.19.3.300. Epub 2013 Sep 30.

5.

Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.

Chi H, Hansen BE, Yim C, Arends P, Abu-Amara M, van der Eijk AA, Feld JJ, de Knegt RJ, Wong DK, Janssen HL.

Aliment Pharmacol Ther. 2015 May;41(9):867-76. doi: 10.1111/apt.13150. Epub 2015 Mar 5.

PMID:
25752878
6.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
7.

Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs.

Sohn HR, Min BY, Song JC, Seong MH, Lee SS, Jang ES, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW.

BMC Infect Dis. 2014 Aug 13;14:439. doi: 10.1186/1471-2334-14-439.

8.

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.

Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF.

Hepatology. 2013 Dec;58(6):1888-96. doi: 10.1002/hep.26549. Epub 2013 Oct 17.

PMID:
23744454
9.

Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.

He D, Guo S, Zhu P, Tao S, Li M, Huang H, Wang J, Wang Y, Ding M.

Clin Microbiol Infect. 2014 Oct;20(10):O687-93. doi: 10.1111/1469-0691.12605. Epub 2014 Mar 24.

10.

Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients.

Jin YJ, Kim KM, Yoo DJ, Shim JH, Lee HC, Chung YH, Lee YS, Suh DJ.

Virol J. 2012 Oct 18;9:239. doi: 10.1186/1743-422X-9-239.

11.

Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.

Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z, Zhu M, Wong VW, Chan HL.

Aliment Pharmacol Ther. 2011 Aug;34(3):344-52. doi: 10.1111/j.1365-2036.2011.04738.x. Epub 2011 Jun 14.

PMID:
21671967
12.

[Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].

Liu DL, Luo KX, Feng XR, Fu QX, Hou JL.

Zhonghua Yi Xue Za Zhi. 2007 Jul 10;87(26):1840-3. Chinese.

PMID:
17922996
13.

Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy.

Byun KS, Kwon OS, Kim JH, Yim HJ, Chang YJ, Kim JY, Yeon JE, Park JJ, Kim JS, Bak YT, Lee CH.

J Gastroenterol Hepatol. 2005 Dec;20(12):1838-42.

PMID:
16336441
14.

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL.

Gastroenterology. 2010 Aug;139(2):491-8. doi: 10.1053/j.gastro.2010.03.059. Epub 2010 Apr 8.

PMID:
20381492
15.

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.

Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.

Am J Gastroenterol. 2005 Nov;100(11):2463-71.

PMID:
16279901
16.

[Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients].

Jung HW, Choi MS, Kim KH, Park SH, Yeon KK, Lee JH, Koh KC, Paik SW, Yoo BC.

Korean J Hepatol. 2009 Mar;15(1):52-8. doi: 10.3350/kjhep.2009.15.1.52. Korean.

17.

Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.

Wang CC, Tseng KC, Peng CY, Hsieh TY, Lin CL, Su TH, Tseng TC, Hsu CS, Lin HH, Kao JH.

J Gastroenterol Hepatol. 2013 Jan;28(1):46-50. doi: 10.1111/j.1440-1746.2012.07269.x.

PMID:
22989322
19.

Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.

Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, Lee YS, Lee CD, Chung KW, Sun HS, Kim BS.

Intervirology. 2005;48(6):341-9.

PMID:
16024938
20.

The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.

Fung J, Lai CL, Tanaka Y, Mizokami M, Yuen J, Wong DK, Yuen MF.

Am J Gastroenterol. 2009 Aug;104(8):1940-6; quiz 1947. doi: 10.1038/ajg.2009.200. Epub 2009 May 19.

PMID:
19455108
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk